FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2802449276> ?p ?o ?g. }

• W2802449276 endingPage "3262" @default.
• W2802449276 startingPage "3253" @default.
• W2802449276 abstract "Abstract Purpose: The PI3K/mTOR pathway is frequently aberrated in cancer. LY3023414 is a potent and selective ATP-competitive inhibitor of class I PI3K isoforms, mTOR, and DNA-PK. Here we report the dose-escalation results of the first-in-human phase I study of LY3023414. Patients and Methods: A 3+3 dose escalation for once-daily and twice-daily oral dosing of LY3023414 was followed by an expansion cohort for CYP3A4 drug–drug interaction (DDI) assessment. The primary objective was to determine the recommended phase 2 dose (RP2D). Additional objectives included safety, pharmacokinetics/pharmacodynamics, and antitumor activity. Results: Forty-seven patients with solid tumors received LY3023414 at once-daily (20–450 mg) or twice-daily dosing (150–250 mg). Dose-limiting toxicities were observed at 450 mg once-daily (thrombocytopenia, hypotension, hyperkalemia) in three of three patients, 250-mg twice-daily dosing (hypophosphatemia, fatigue, mucositis) in three of four patients, and in one of 15 patients at 200 mg twice-daily (nausea). Common related AEs included nausea (38%), fatigue (34%), and vomiting (32%) and were mostly mild or moderate. LY3023414 pharmacokinetics demonstrated dose-dependent increase in exposure with ≥ 90% target inhibition at doses ≥150 mg. DDI analysis demonstrated LY3023414 to be a weak inhibitor of CYP3A4. Durable partial response was observed in a patient with endometrial cancer harboring PIK3R1 and PTEN truncating mutations, and 13 additional patients (28%) had a decrease in their target lesions by up to 30%. Conclusions: LY3023414 has a tolerable safety profile and single-agent activity in patients with advanced cancers. The RP2D of LY3023414 monotherapy is 200 mg twice daily based on safety, tolerability, and pharmacokinetic/pharmacodynamic data. Clin Cancer Res; 24(14); 3253–62. ©2018 AACR." @default.
• W2802449276 created "2018-05-17" @default.
• W2802449276 creator A5009244604 @default.
• W2802449276 creator A5027467209 @default.
• W2802449276 creator A5028472820 @default.
• W2802449276 creator A5035801178 @default.
• W2802449276 creator A5037195922 @default.
• W2802449276 creator A5051346978 @default.
• W2802449276 creator A5051542505 @default.
• W2802449276 creator A5053450523 @default.
• W2802449276 creator A5068193017 @default.
• W2802449276 creator A5069337573 @default.
• W2802449276 creator A5084349853 @default.
• W2802449276 creator A5088191549 @default.
• W2802449276 date "2018-07-15" @default.
• W2802449276 modified "2023-10-10" @default.
• W2802449276 title "A First-in-Human Phase 1 Study of LY3023414, an Oral PI3K/mTOR Dual Inhibitor, in Patients with Advanced Cancer" @default.
• W2802449276 cites W1967013964 @default.
• W2802449276 cites W1992477322 @default.
• W2802449276 cites W2001999652 @default.
• W2802449276 cites W2006771504 @default.
• W2802449276 cites W2010559088 @default.
• W2802449276 cites W2019607817 @default.
• W2802449276 cites W2027798661 @default.
• W2802449276 cites W2032500497 @default.
• W2802449276 cites W2038444072 @default.
• W2802449276 cites W2041440766 @default.
• W2802449276 cites W2059788609 @default.
• W2802449276 cites W2067019627 @default.
• W2802449276 cites W2076293231 @default.
• W2802449276 cites W2097665491 @default.
• W2802449276 cites W2123540640 @default.
• W2802449276 cites W2126783165 @default.
• W2802449276 cites W2129159987 @default.
• W2802449276 cites W2141125222 @default.
• W2802449276 cites W2150174916 @default.
• W2802449276 cites W2160981405 @default.
• W2802449276 cites W2165404212 @default.
• W2802449276 cites W2167264978 @default.
• W2802449276 cites W2283437222 @default.
• W2802449276 cites W2497200850 @default.
• W2802449276 cites W2518718875 @default.
• W2802449276 cites W2788744735 @default.
• W2802449276 doi "https://doi.org/10.1158/1078-0432.ccr-17-3421" @default.
• W2802449276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29636360" @default.
• W2802449276 hasPublicationYear "2018" @default.
• W2802449276 type Work @default.
• W2802449276 sameAs 2802449276 @default.
• W2802449276 citedByCount "60" @default.
• W2802449276 countsByYear W28024492762018 @default.
• W2802449276 countsByYear W28024492762019 @default.
• W2802449276 countsByYear W28024492762020 @default.
• W2802449276 countsByYear W28024492762021 @default.
• W2802449276 countsByYear W28024492762022 @default.
• W2802449276 countsByYear W28024492762023 @default.
• W2802449276 crossrefType "journal-article" @default.
• W2802449276 hasAuthorship W2802449276A5009244604 @default.
• W2802449276 hasAuthorship W2802449276A5027467209 @default.
• W2802449276 hasAuthorship W2802449276A5028472820 @default.
• W2802449276 hasAuthorship W2802449276A5035801178 @default.
• W2802449276 hasAuthorship W2802449276A5037195922 @default.
• W2802449276 hasAuthorship W2802449276A5051346978 @default.
• W2802449276 hasAuthorship W2802449276A5051542505 @default.
• W2802449276 hasAuthorship W2802449276A5053450523 @default.
• W2802449276 hasAuthorship W2802449276A5068193017 @default.
• W2802449276 hasAuthorship W2802449276A5069337573 @default.
• W2802449276 hasAuthorship W2802449276A5084349853 @default.
• W2802449276 hasAuthorship W2802449276A5088191549 @default.
• W2802449276 hasBestOaLocation W28024492761 @default.
• W2802449276 hasConcept C111113717 @default.
• W2802449276 hasConcept C112705442 @default.
• W2802449276 hasConcept C121608353 @default.
• W2802449276 hasConcept C126322002 @default.
• W2802449276 hasConcept C143998085 @default.
• W2802449276 hasConcept C197934379 @default.
• W2802449276 hasConcept C2777288759 @default.
• W2802449276 hasConcept C2778375690 @default.
• W2802449276 hasConcept C2778496288 @default.
• W2802449276 hasConcept C2780580376 @default.
• W2802449276 hasConcept C2780852908 @default.
• W2802449276 hasConcept C29730261 @default.
• W2802449276 hasConcept C71924100 @default.
• W2802449276 hasConcept C98274493 @default.
• W2802449276 hasConceptScore W2802449276C111113717 @default.
• W2802449276 hasConceptScore W2802449276C112705442 @default.
• W2802449276 hasConceptScore W2802449276C121608353 @default.
• W2802449276 hasConceptScore W2802449276C126322002 @default.
• W2802449276 hasConceptScore W2802449276C143998085 @default.
• W2802449276 hasConceptScore W2802449276C197934379 @default.
• W2802449276 hasConceptScore W2802449276C2777288759 @default.
• W2802449276 hasConceptScore W2802449276C2778375690 @default.
• W2802449276 hasConceptScore W2802449276C2778496288 @default.
• W2802449276 hasConceptScore W2802449276C2780580376 @default.
• W2802449276 hasConceptScore W2802449276C2780852908 @default.
• W2802449276 hasConceptScore W2802449276C29730261 @default.
• W2802449276 hasConceptScore W2802449276C71924100 @default.
• W2802449276 hasConceptScore W2802449276C98274493 @default.
• W2802449276 hasIssue "14" @default.

• next